cancer therapy

Another Bright Path for ADC Development – Non-Internalizing ADC

by
Another Bright Path for ADC Development - Non-Internalizing ADC

Antibody-Drug Conjugates (ADC) typically require internalization to release their cytotoxic payload. However, there are strict limitations, requiring high expression of internalizing antigens and efficient intracellular processing. A new method has emerged, allowing the payload to be released extracellularly from cleavable linkers after binding to poorly internalizing antigens or other tumor components. This method eliminates the … Read more

Overview of Currently Approved Antibody Drug Conjugates (ADCs)

by
Overview of Currently Approved Antibody Drug Conjugates (ADCs)

Antibody Drug Conjugates (ADCs) are a new type of targeted anti-tumor therapy. They combine the targeting capability of monoclonal antibodies with the cytotoxic effects of highly effective chemotherapeutic agents, primarily used for the treatment of various refractory cancers. ADCs precisely identify and attack cancer cells while minimizing damage to normal cells, thus exhibiting high efficiency … Read more

Innovative Delivery: Comprehensive Analysis of ‘Magic Bullet’ ADC Drug Screening

by
Innovative Delivery: Comprehensive Analysis of 'Magic Bullet' ADC Drug Screening

Authors: Li Jiaxing, Hu Linghong, Hu YuhaoImages: Yang Zhenzhen1. Summary Antibody-drug conjugates (ADCs) rejuvenate the concept of targeted chemotherapy by coupling cytotoxic payloads to antibodies. The first stage of the complex intracellular toxin delivery process of ADCs is endocytosis. Analyzing the endocytosis of target receptors and ADCs can greatly enhance preclinical studies, clinical translation, and … Read more

The Future of c-MET: Dual Antibodies, ADCs, or New Technologies?

by
The Future of c-MET: Dual Antibodies, ADCs, or New Technologies?

1 Introduction c-MET [also known as MET tyrosine protein kinase or hepatocyte growth factor receptor (HGFR)] is a protein encoded by the MET gene. c-MET is crucial for embryonic development, organ growth, and wound healing. Hepatocyte growth factor (HGF) is the ligand for the c-MET receptor. MET is typically expressed by epithelial-derived cells, but can … Read more

In-Depth Review of ADC Drug Development and Future Directions

by
In-Depth Review of ADC Drug Development and Future Directions

Antibody-drug conjugates (ADCs) consist of linker, payload, and monoclonal antibodies (mAb). They combine the advantages of high specificity targeting ability and potent cytotoxic effects, achieving precise and efficient destruction of cancer cells, making them one of the hot topics in anticancer drug development.Since the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was approved by the FDA … Read more

ADC Technology Report: Forecast of Next-Generation ADC Development

by
ADC Technology Report: Forecast of Next-Generation ADC Development

Antibody-drug conjugates (ADCs) have become a popular avenue in tumor treatment in recent years, typically covalently linking monoclonal antibodies (mAbs) with cytotoxic drugs (payloads) via chemically synthesized linkers. ADCs combine the advantages of highly specific targeting capabilities and effective killing actions, achieving precise and efficient clearance of cancer cells.Figure 1. Structure and characteristics of ADC … Read more

Overview of ADC Linker and Connector Technologies

by
Overview of ADC Linker and Connector Technologies

▲May 2022, Improved New Drug Trends and Technology Conference·Limited TimeFree Registration Ongoing Note:This article does not constitute any investment opinions or advice, subject to official/company announcements;This article is only for the introduction of medical health-related drugs, not a recommendation for treatment plans (if involved), and does not represent the platform’s position.Any article reproduction requires authorization. … Read more

In-Depth Review of ADC Drug Development: History, Challenges, and Future Directions

by
In-Depth Review of ADC Drug Development: History, Challenges, and Future Directions

Since the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was approved by the FDA in 2000, as of December 2021, a total of 14 ADC drugs have been approved globally for hematological malignancies and solid tumors, and currently, there are over 100 ADC candidates at various stages of clinical trials. Recently, the journal Signal Transduction and … Read more

The Next Step for Bispecific Antibodies: Bispecific ADC?

by
The Next Step for Bispecific Antibodies: Bispecific ADC?

Bispecific antibodies are antibodies that can bind to two different antigens simultaneously, providing greater flexibility in their mechanisms of action. Bispecific antibodies have achieved success in hematologic malignancies, with two bispecific antibodies already approved for market: blinatumomab, targeting CD19/CD3, and Mosunetuzumab, targeting CD20/CD3. Additionally, numerous bispecific antibodies targeting hematologic cancers have shown impressive efficacy in … Read more

Structure and Function of Antibody-Drug Conjugates (ADC)

by

Previous Reviews 2023 Overview of Antibody Drug Industry Development History of Monoclonal Antibodies, This Article is Enough! Brief Discussion on the Mechanism of Action and Advantages/Disadvantages of Antibodies How to Name Monoclonal Antibodies, Read This! Magic Bullet – ADC Antibody-drug conjugates (ADC) are a class of targeted biological agents composed of an antibody, a linker, … Read more